JP5888654B2 - 疾患の治療のためのヒスタミン受容体の複素環阻害薬 - Google Patents

疾患の治療のためのヒスタミン受容体の複素環阻害薬 Download PDF

Info

Publication number
JP5888654B2
JP5888654B2 JP2012557231A JP2012557231A JP5888654B2 JP 5888654 B2 JP5888654 B2 JP 5888654B2 JP 2012557231 A JP2012557231 A JP 2012557231A JP 2012557231 A JP2012557231 A JP 2012557231A JP 5888654 B2 JP5888654 B2 JP 5888654B2
Authority
JP
Japan
Prior art keywords
mmol
thiophen
compound
pyrazine
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2012557231A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013522222A5 (enExample
JP2013522222A (ja
Inventor
ボーチャート，アレン
デイビス，ロバート
ノーブル，スチュワート，エー．
Original Assignee
カリプシス，インク
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by カリプシス，インク filed Critical カリプシス，インク
Publication of JP2013522222A publication Critical patent/JP2013522222A/ja
Publication of JP2013522222A5 publication Critical patent/JP2013522222A5/ja
Application granted granted Critical
Publication of JP5888654B2 publication Critical patent/JP5888654B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2012557231A 2010-03-10 2011-03-10 疾患の治療のためのヒスタミン受容体の複素環阻害薬 Expired - Fee Related JP5888654B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31261510P 2010-03-10 2010-03-10
US61/312,615 2010-03-10
PCT/US2011/027817 WO2011112766A2 (en) 2010-03-10 2011-03-10 Heterocyclic inhibitors of histamine receptors for the treatment of disease

Publications (3)

Publication Number Publication Date
JP2013522222A JP2013522222A (ja) 2013-06-13
JP2013522222A5 JP2013522222A5 (enExample) 2014-04-24
JP5888654B2 true JP5888654B2 (ja) 2016-03-22

Family

ID=44564108

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012557231A Expired - Fee Related JP5888654B2 (ja) 2010-03-10 2011-03-10 疾患の治療のためのヒスタミン受容体の複素環阻害薬

Country Status (18)

Country Link
US (1) US8569300B2 (enExample)
EP (1) EP2545058B1 (enExample)
JP (1) JP5888654B2 (enExample)
KR (1) KR20130016253A (enExample)
CN (1) CN102869666B (enExample)
AR (1) AR080496A1 (enExample)
AU (1) AU2011224316B2 (enExample)
BR (1) BR112012022211A2 (enExample)
CA (1) CA2791417A1 (enExample)
ES (1) ES2607125T3 (enExample)
IL (1) IL221829A (enExample)
MX (1) MX2012010404A (enExample)
NZ (1) NZ602041A (enExample)
PH (1) PH12012501783A1 (enExample)
RU (1) RU2012137180A (enExample)
TW (1) TW201200518A (enExample)
UY (1) UY33271A (enExample)
WO (1) WO2011112766A2 (enExample)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8859550B2 (en) * 2011-09-12 2014-10-14 Kalypsys, Inc. Heterocyclic inhibitors of histamine receptors for the treatment of disease
US9266891B2 (en) 2012-11-16 2016-02-23 Boehringer Ingelheim International Gmbh Substituted [1,2,4]triazolo[4,3-A]pyrazines that are BRD4 inhibitors
MD20150103A2 (ro) 2013-05-02 2016-02-29 Pfizer Inc. Derivaţi ai imidazo-triazinei ca inhibitori ai PDE10
EP3290407B1 (en) 2013-10-18 2020-01-01 Celgene Quanticel Research, Inc Bromodomain inhibitors
WO2015123424A1 (en) 2014-02-13 2015-08-20 Incyte Corporation Cyclopropylamines as lsd1 inhibitors
LT3105218T (lt) 2014-02-13 2019-12-10 Incyte Corp Ciklopropilaminai kaip lsd1 inhibitoriai
EP3392244A1 (en) 2014-02-13 2018-10-24 Incyte Corporation Cyclopropylamines as lsd1 inhibitors
US9527835B2 (en) 2014-02-13 2016-12-27 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
US9758523B2 (en) 2014-07-10 2017-09-12 Incyte Corporation Triazolopyridines and triazolopyrazines as LSD1 inhibitors
WO2016007731A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Imidazopyridines and imidazopyrazines as lsd1 inhibitors
WO2016007722A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
WO2016007736A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Imidazopyrazines as lsd1 inhibitors
TW201625635A (zh) 2014-11-21 2016-07-16 默沙東藥廠 作為可溶性鳥苷酸環化酶活化劑之三唑并吡基衍生物
MX375970B (es) 2014-12-23 2025-03-06 Novartis Ag Compuestos de triazolopirimidina y usos de los mismos.
EA201792205A1 (ru) 2015-04-03 2018-02-28 Инсайт Корпорейшн Гетероциклические соединения как ингибиторы lsd1
DK3334709T3 (da) 2015-08-12 2025-02-03 Incyte Holdings Corp Salte af en lsd1-hæmmer
CA3021678A1 (en) 2016-04-22 2017-10-26 Incyte Corporation Formulations of an lsd1 inhibitor
JP7042812B2 (ja) 2016-06-20 2022-03-28 ノバルティス アーゲー トリアゾロピリミジン化合物の結晶形態
US10689378B2 (en) 2016-06-20 2020-06-23 Novartis Ag Triazolopyridine compounds and uses thereof
JP2019524872A (ja) 2016-06-20 2019-09-05 ノバルティス アーゲー 癌の治療に有用なイミダゾピリミジン化合物
TW201837026A (zh) 2017-01-10 2018-10-16 德商拜耳廠股份有限公司 作為除害劑之雜環衍生物（二）
KR102515694B1 (ko) 2017-01-10 2023-03-29 바이엘 악티엔게젤샤프트 해충 방제제로서의 헤테로사이클 유도체
CN110446709B (zh) 2017-01-23 2023-09-12 锐新医药公司 作为变构shp2抑制剂的二环化合物
CN111032646B (zh) 2017-08-01 2023-01-03 施万生物制药研发Ip有限责任公司 作为jak激酶抑制剂的吡唑并和三唑并双环化合物
BR112020007058A2 (pt) * 2017-10-12 2020-10-06 Revolution Medicines, Inc. compostos de piridina, pirazina, e triazina como inibidores de shp2 alostéricos
BR112020009757A2 (pt) * 2017-12-15 2020-11-03 Revolution Medicines, Inc. compostos policíclicos como inibidores alostéricos de shp2
US11498930B2 (en) 2018-02-13 2022-11-15 Blueray Therapeutics (Shanghai) Co., Ltd Pyrimidine-fused cyclic compound, preparation method therefor and application thereof
CN115448923B (zh) * 2018-02-13 2024-03-22 上海青煜医药科技有限公司 嘧啶并环化合物及其制备方法和应用
CN110655520A (zh) * 2018-06-29 2020-01-07 上海青煜医药科技有限公司 嘧啶并环化合物及其制备方法和应用
AU2019227607C1 (en) 2018-02-27 2023-07-20 Incyte Corporation Imidazopyrimidines and triazolopyrimidines as A2A / A2B inhibitors
EP3810610A1 (en) 2018-05-18 2021-04-28 Incyte Corporation Fused pyrimidine derivatives as a2a / a2b inhibitors
CN117304191A (zh) 2018-07-05 2023-12-29 因赛特公司 作为a2a/a2b抑制剂的稠合吡嗪衍生物
US10968200B2 (en) 2018-08-31 2021-04-06 Incyte Corporation Salts of an LSD1 inhibitor and processes for preparing the same
WO2020068729A1 (en) 2018-09-25 2020-04-02 Incyte Corporation Pyrazolo[4,3-d]pyrimidine compounds as alk2 abd/or fgfr modulators
US12281118B2 (en) 2018-11-07 2025-04-22 Shanghai Ringene Biopharma Co., Ltd. Nitrogen-containing fused heterocyclic SHP2 inhibitor compound, preparation method, and use
WO2020108590A1 (zh) * 2018-11-30 2020-06-04 上海拓界生物医药科技有限公司 嘧啶并五元氮杂环类衍生物、其制备方法及其在医药上的应用
CN113498352A (zh) 2019-01-23 2021-10-12 施万生物制药研发Ip有限责任公司 作为jak抑制剂的咪唑并[1,5-a]吡啶、1,2,4-三唑并[4,3-a]吡啶和咪唑并[1,5-a]吡嗪
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
JP7357146B2 (ja) * 2019-08-22 2023-10-05 ブルーレイ セラピューティクス （シャンハイ） カンパニー，リミティド アザヘテロアリール化合物及びその使用
US12065444B2 (en) 2021-11-19 2024-08-20 Crossignal Therapeutics, Inc. Substituted tetrazolo[1,5-a]pyrazines and tetrazolo[1,5-c]pyrimidines as adenosine receptor antagonists

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3929812A (en) * 1974-05-20 1975-12-30 Squibb & Sons Inc Derivatives of 1H-triazolo {8 4,5-c{9 pyridine-7-carboxylic acids and esters
DE4337611A1 (de) * 1993-11-04 1995-05-11 Boehringer Ingelheim Kg Neue Benzoylguanidine, ihre Herstellung und ihre Verwendung in Arzneimitteln
EP1430898A4 (en) * 2001-09-28 2005-11-02 Kyowa Hakko Kogyo Kk Receptor antagonist
US6921762B2 (en) * 2001-11-16 2005-07-26 Amgen Inc. Substituted indolizine-like compounds and methods of use
CN1310916C (zh) * 2002-06-25 2007-04-18 协和发酵工业株式会社 双环类杂环化合物
MXPA05002575A (es) 2002-09-06 2005-09-08 Johnson & Johnson Compuestos heterociclicos.
DK1753764T3 (da) * 2004-06-09 2009-02-16 Glaxo Group Ltd Pyrrolopyridin-derivater
WO2007063934A1 (ja) * 2005-12-02 2007-06-07 Mitsubishi Tanabe Pharma Corporation 脂環式複素環化合物
US7807671B2 (en) * 2006-04-25 2010-10-05 Bristol-Myers Squibb Company Diketo-piperazine and piperidine derivatives as antiviral agents
HRP20100378T1 (hr) * 2006-05-31 2010-08-31 Galapagos N.V. Spojevi triazolopirazina učinkoviti za tretman degenerativnih i upalnih bolesti
AU2007271187A1 (en) 2006-07-03 2008-01-10 Vereniging Voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek En Patientenzorg Fused bicyclic compounds interacting with the histamine H4 receptor
EP2066645A2 (en) 2006-09-12 2009-06-10 UCB Pharma S.A. 2 amino-pyrimidine derivatives as h4 receptor antagonists, processes for preparing them and their use in pharmaceutical compositions
US8952160B2 (en) 2008-01-11 2015-02-10 Fibrogen, Inc. Isothiazole-pyridine derivatives as modulators of HIF (hypoxia inducible factor) activity
JP5769972B2 (ja) * 2008-02-08 2015-08-26 バジリア ファルマスーチカ アーゲーＢａｓｉｌｅａ Ｐｈａｒｍａｃｅｕｔｉｃａ ＡＧ Ｐｄｅ阻害により仲介される疾患を処置するためのマクロライド
AR073739A1 (es) * 2008-09-10 2010-12-01 Kalypsys Inc Aminopirimidinas como inhibidores de los receptores de histamina
JP2012502067A (ja) * 2008-09-10 2012-01-26 カリプシス・インコーポレーテッド 疾患の治療のためのヒスタミン受容体の複素環阻害剤
NZ596185A (en) * 2009-04-16 2013-01-25 Ct Nac Investigaciones Oncologicas Cnio Imidazopyrazines for use as kinase inhibitors
WO2011019780A1 (en) * 2009-08-11 2011-02-17 Bristol-Myers Squibb Company Azaindazoles as btk kinase modulators and use thereof
PT3078664T (pt) 2009-12-17 2019-05-31 Boehringer Ingelheim Animal Health Usa Inc Composições antiparasitárias de di-hidroazoles
CA2787714C (en) 2010-01-22 2019-04-09 Joaquin Pastor Fernandez Inhibitors of pi3 kinase
US20110190269A1 (en) * 2010-02-01 2011-08-04 Karlheinz Baumann Gamma secretase modulators
WO2011112687A2 (en) 2010-03-10 2011-09-15 Kalypsys, Inc. Heterocyclic inhibitors of histamine receptors for the treatment of disease

Also Published As

Publication number Publication date
AR080496A1 (es) 2012-04-11
PH12012501783A1 (en) 2015-06-26
WO2011112766A3 (en) 2012-01-19
AU2011224316B2 (en) 2016-09-15
WO2011112766A2 (en) 2011-09-15
KR20130016253A (ko) 2013-02-14
CN102869666A (zh) 2013-01-09
EP2545058A4 (en) 2013-07-24
US20110237565A1 (en) 2011-09-29
UY33271A (es) 2011-10-31
IL221829A (en) 2014-11-30
ES2607125T3 (es) 2017-03-29
BR112012022211A2 (pt) 2017-07-18
RU2012137180A (ru) 2014-04-20
NZ602041A (en) 2014-08-29
US8569300B2 (en) 2013-10-29
AU2011224316A1 (en) 2012-09-13
TW201200518A (en) 2012-01-01
CA2791417A1 (en) 2011-09-15
CN102869666B (zh) 2015-09-09
EP2545058B1 (en) 2016-08-24
EP2545058A2 (en) 2013-01-16
MX2012010404A (es) 2013-05-20
JP2013522222A (ja) 2013-06-13

Similar Documents

Publication Publication Date Title
EP2545058B1 (en) TETRAZOLO[1,5-a]PYRAZINE COMPOUNDS AS INHIBITORS OF HISTAMINE RECEPTORS
US20120065187A1 (en) Heterocyclic inhibitors of histamine receptors for the treatment of disease
US10093664B2 (en) Bicyclo[1.1.1]pentane inhibitors of dual leucine zipper (DLK) kinase for the treatment of disease
US20110257137A1 (en) Heterocyclic inhibitors of histamine receptors for the treatment of disease
CN102186479A (zh) 用于治疗疾病的组胺受体的氨基嘧啶抑制剂
US8080566B1 (en) Carbazole inhibitors of histamine receptors for the treatment of disease
US20110237599A1 (en) Heterocyclic inhibitors of histamine receptors for the treatment of disease
US20230008047A1 (en) Imidazopiperazine inhibitors of transcription activating proteins
KR20150074004A (ko) Pde4 의 헤테로아릴 저해제
JP6895396B2 (ja) 疾患を処置するためのｇｌｓ１阻害薬
JP2022531088A (ja) Ｊａｋ阻害剤としての置換ピロロピリジン
US11713320B2 (en) 5-heteroaryl substituted indazole-3-carboxamides and preparation and use thereof
US20190135793A1 (en) Heterocyclic inhibitors of kdm5 for the treatment of disease
HK1181038B (en) Tetrazolo[1,5-a]pyrazine compounds as inhibitors of histamine receptors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130710

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140305

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140307

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20150130

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150225

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150521

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150622

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150721

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150824

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160125

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160205

R150 Certificate of patent or registration of utility model

Ref document number: 5888654

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees